Browse the evidence

MetFlex to fat showed no correlation to MetFlex measured during the clamp.

Different methods may yield different insights into metabolic flexibility.

Approximately 83.0% of patients in both treatment groups receive TSH testing within a 1-year follow-up.

Practitioners should note that a high percentage of older adults on levothyroxine are monitored for TSH after initiating GLP-1 RAs.

TSH testing patterns did not differ between GLP-1 RAs and SGLT-2is.

Clinicians can expect similar TSH monitoring practices regardless of whether patients are on GLP-1 RAs or SGLT-2is.

The mean time to TSH testing was approximately 130.5 days for both groups.

Practitioners should be aware that TSH testing occurs on average about 130 days after treatment initiation.

Future research should standardize economic evaluation methods in SET studies for better comparison across diverse interventions, settings, and populations.

Researchers should aim for consistent evaluation methods to enhance the validity of findings in SET studies.

There is significant societal attention on the issues of overweight and obesity.

Practitioners should be aware of the societal context when addressing obesity in patients.

Effective nephroprotection requires early identification of at-risk patients through screening.

Implement routine screening for CKD risk factors in clinical practice.

Few diabetes prevention program (DPP) studies investigate why these interventions work.

Practitioners should be aware that the mechanisms behind DPP effectiveness are not well understood.

There is no compelling evidence to support any specific mechanism, mediator, or moderator (MMM) in DPPs.

Practitioners should consider that current evidence does not support specific mechanisms in DPPs.

Patients had lower energy and protein intake from oral food intake following the implementation of the tailored nutrition protocol.

Practitioners should be aware that increased enteral feeding may lead to reduced oral intake.

Cheeses improved C. elegans lifespan, mobility with aging, and age-related muscle degradation.

Incorporating these cheeses may support longevity and mobility in aging populations.

MitoQ supplementation did not impact mitochondrial respiration or H2O2 emission in the presence of ADP.

MitoQ does not enhance mitochondrial function during exercise in older adults.

MitoQ supplementation did not alter acute exercise-induced redox responses in skeletal muscle.

MitoQ does not affect redox signaling during acute exercise in older adults.

HbA1C levels increase alongside the duration of illness in individuals with type 2 diabetes.

Practitioners should monitor HbA1C levels to assess disease progression in diabetic patients.

No significant associations with cognitive function were found for physical activity or adiposity.

Physical activity and adiposity may not be effective targets for improving cognitive function in this population.

Individuals in the younger onset T2D subgroup have the lowest risk for peripheral neuropathy.

Younger individuals with T2D may require different monitoring for PN risk.

The impact of intensive lifestyle intervention (ILI) on peripheral neuropathy risk does not differ by T2D subgroups.

ILI may not be effective in reducing PN risk across different T2D subgroups.

Human hypothalamic melanocortin neurons (POMC and AgRP) exhibit significant transcriptomic and receptor-expression differences compared to mice, including species-specific GPCR profiles that directly impact the mechanism and efficacy of current obesity therapies.

Current obesity treatments like semaglutide and tirzepatide target the hypothalamus, but their exact molecular mechanisms in humans may differ from what we learned from mouse studies. This map reveals that human POMC neurons express different receptors (like CALCR) than mouse POMC neurons. This means drug developers must account for these human-specific differences to improve efficacy and reduce side effects, rather than relying solely on rodent data.

Secure multi-party computation (MPC) enables the linkage of patient data across different hospitals for research purposes without violating privacy regulations, allowing for accurate assessment of hospital transfer rates.

This paper is primarily for researchers and healthcare administrators. It demonstrates that advanced privacy-preserving technology (MPC) can be used to link patient data across hospitals, enabling more accurate research on patient outcomes and behaviors, such as hospital transfers.

There is a significant disconnect between mechanistic research (e.g., mTOR signaling) and applied intervention studies, leading to a lack of systematic translation of basic science into concrete intervention strategies.

Current research often fails to bridge the gap between molecular science and practical advice. For now, focus on the proven basics: consistent resistance training and adequate protein intake, rather than trying to optimize based on complex molecular mechanisms that haven't been fully translated into practical protocols.

SGLT2 inhibitors reduce the risk of heart failure hospitalization and cardiovascular death in patients with heart failure with reduced ejection fraction (HFrEF), regardless of diabetes status.

If you have heart failure, especially with reduced ejection fraction, ask your doctor about SGLT2 inhibitors like empagliflozin or dapagliflozin. These drugs help your heart pump better and reduce hospitalizations, even if you don't have diabetes.

Without immediate and effective intervention, the global prevalence of adult overweight and obesity will continue to increase, reaching 3.80 billion adults by 2050.

The current trajectory of global obesity is unsustainable and will affect over half the adult population by 2050. Individuals and policymakers must move beyond simple awareness and implement aggressive, targeted interventions tailored to local contexts to prevent this crisis.

A once-weekly synthetic semaglutide formulation (test drug) provides weight loss efficacy and safety comparable to the innovator semaglutide (Wegovy) in Indian adults with obesity over a 24-week period.

If you are an adult in India with obesity who has struggled to lose weight through diet and exercise alone, this study shows that a once-weekly synthetic semaglutide injection works just as well as the brand-name version (Wegovy) over 24 weeks. You can expect to lose about 14-15% of your body weight if you follow the dose-titration schedule (starting low and increasing every 4 weeks) alongside a 500-calorie daily deficit and 150 minutes of weekly exercise. While you may experience common side effects like nausea or constipation, they are generally mild and manageable. This option may be more affordable than the brand name, making it a viable long-term management tool.

Tirzepatide produces significantly greater weight loss than semaglutide in adults with obesity or overweight, with the magnitude of loss increasing with higher doses (>10 mg) and longer treatment durations (>6 months).

If you are using semaglutide and not achieving your weight loss goals, switching to tirzepatide (particularly at doses above 10 mg and continuing for more than 6 months) is likely to result in significantly greater weight loss. The data supports tirzepatide as a more potent option for reducing body weight compared to semaglutide.